Why carry out this study?

Migraine is experienced by an estimated 14% of the global population and is responsible for reduced quality of life in those afflicted.

There is little reported evidence about the tolerability and safety of combining CGRP mAbs and gepants, particularly in an underreported population.

What did this study ask?

The current retrospective study sought to investigate the safety and tolerability of combined treatment.

What were the study outcomes/conclusions?

Three adverse events were reported on this combination; however, they did not lead to the discontinuation of treatment.

What was learned from the study?

The combination of CGRP mAbs and gepants was well tolerated and safe in the 234 patients included in this study.